

ACRO Testifies Before FDA on Clinical Trial Modernization

WASHINGTON—(BUSINESS WIRE)—

The Association of Clinical Research Organizations (ACRO) today provided the FDA with a number of suggestions to improve the drug development process, highlighted by a call to appoint a Chief Innovation Officer within the agency. ACRO's recommendations were included in testimony presented by Executive Director Doug Peddicord, Ph.D., at a public hearing titled Modernizing the Regulation of Clinical Trials and Approaches to Good Clinical Practice